SHOULD ANTI-CGRP MONOCLONAL ANTIBODIES ALWAYS BE THE DRUG OF FIRST CHOICE FOR MIGRAINE PROPHYLAXIS IN BRAZIL? - A PHARMACOECONOMIC STUDY
Open Access
- 30 September 2024
- journal article
- Published by Headache Medicine in Headache Medicine
- Vol. 15 (3) , 170-174
Abstract
Efficacy (success of therapy under ideal conditions), efficiency (the relationship between the costs and outcomes of a specific intervention), and effectiveness (the balance between efficacy and efficiency in clinical practice) are measures used to evaluate health interventions. Thus, in private practice and the public health system, the knowledge of these pharmacoeconomic data should influence the appropriate treatment choice. Migraine prophylaxis falls within this context. Traditional medications are available in the public health system, while galcanezumab is not routinely available. The present study aims to analyze the efficacy and effectiveness of galcanezumab and traditional therapeutic alternatives (amitriptyline, divalproex sodium, and topiramate). Efficacy data were obtained from the relevant literature (PubMed) and cost values from the ABCFARMA magazine. The economic impact analysis considered the cost of living for an economically active adult in Brazil based on the Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística, IBGE) and the Institute for Applied Economic Research (Instituto de Pesquisa Econômica Aplicada, IPEA). Efficacy: amitriptyline: 40%; divalproex sodium: 30%; topiramate: 31%; galcanezumab: 50%. Their annual costs were: amitriptyline R$ 240.00; sodium divalproate R$ 876.00; topiramate R$ 600.00; galcanezumab R$ 13,992.00. Efficiency: amitriptyline 200%; divalproex sodium 41.1%; topiramate 62%; galcanezumab 4%. Ultimately, effectiveness is amitriptyline 120%; divalproex sodium 35.7%; topiramate 46.5%; galcanezumab 27%. Galcanezumab is the most effective; however, in a broader analysis, where payers, availability, and patient conditions are considered, evaluating efficacy alone may not be feasible in practical contexts and, therefore, anti-CGRP antibodies will not always be the first-line medications in migraine prophylaxis.Keywords
This publication has 25 references indexed in Scilit:
- Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement updateHeadache: The Journal of Head and Face Pain, 2024
- Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part IArquivos de Neuro-Psiquiatria, 2022
- Migraine Progression: A Systematic ReviewHeadache: The Journal of Head and Face Pain, 2018
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical PracticeHeadache: The Journal of Head and Face Pain, 2018
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia, 2018
- Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine preventionJournal of Neurology, Neurosurgery & Psychiatry, 2016
- The Prevalence and Impact of Headache in B razilHeadache: The Journal of Head and Face Pain, 2015
- Preventive Pharmacotherapy in MigraineHeadache: The Journal of Head and Face Pain, 2013
- Calcitonin Gene‐Related Peptide (CGRP) and MigraineHeadache: The Journal of Head and Face Pain, 2006
- Effectiveness, efficiency, and NICEBMJ, 2001